Detalhe da pesquisa
1.
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
N Engl J Med
; 381(25): 2403-2415, 2019 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-31562800
2.
Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone.
World J Surg Oncol
; 16(1): 191, 2018 Sep 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-30231890
3.
Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2.
Gynecol Oncol
; 143(1): 27-34, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-27546885
4.
Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone.
Ann Surg Oncol
; 22(9): 2860-8, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26033180
5.
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Lancet Oncol
; 14(8): 697-710, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23746666
6.
Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.
Clin Lung Cancer
; 23(3): 214-225, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35331641
7.
A Population Pharmacokinetic Meta-Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients.
J Clin Pharmacol
; 61(9): 1195-1205, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33894017
8.
Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial.
Ther Adv Med Oncol
; 13: 17588359211059601, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34917174
9.
Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study.
Lung Cancer
; 161: 180-188, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34607210
10.
Efficacy and safety of first-line veliparib and carboplatin-paclitaxel in patients with HER2- advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial.
Eur J Cancer
; 154: 35-45, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34243076
11.
Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer.
Lung Cancer
; 159: 56-65, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34311345
12.
Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study.
J Clin Oncol
; 39(32): 3633-3644, 2021 11 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34436928
13.
Failure of anti-EGFR therapy in p16-positive head and neck cancer - authors' reply.
Lancet Oncol
; 14(11): e437-e438, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24079867
14.
Clinical validation of the next-generation sequencing-based Extended RAS Panel assay using metastatic colorectal cancer patient samples from the phase 3 PRIME study.
J Cancer Res Clin Oncol
; 144(10): 2001-2010, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-30019318
15.
ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer.
Eur J Cancer
; 70: 111-121, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27914241
16.
Population-based study of giant cell tumor of bone in Sweden (1983-2011).
Cancer Epidemiol
; 42: 82-9, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27060625
17.
Incidence Trends in the Diagnosis of Giant Cell Tumor of Bone in Sweden Since 1958.
J Bone Joint Surg Am
; 97(21): 1756-66, 2015 Nov 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-26537163
18.
First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study.
Eur J Cancer
; 48(4): 547-63, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22240283